Versor Investments LP Has $1.01 Million Stock Holdings in IQVIA Holdings Inc. $IQV

Versor Investments LP grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 94.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,398 shares of the medical research company’s stock after purchasing an additional 3,102 shares during the quarter. Versor Investments LP’s holdings in IQVIA were worth $1,008,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in IQV. Pacer Advisors Inc. lifted its stake in shares of IQVIA by 5,036.1% in the 1st quarter. Pacer Advisors Inc. now owns 871,704 shares of the medical research company’s stock valued at $153,681,000 after purchasing an additional 854,732 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company’s stock valued at $448,686,000 after purchasing an additional 798,534 shares during the period. Nordea Investment Management AB lifted its stake in shares of IQVIA by 41.7% in the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after purchasing an additional 606,391 shares during the period. Hawk Ridge Capital Management LP acquired a new position in IQVIA during the 1st quarter worth approximately $77,096,000. Finally, Nuveen LLC acquired a new position in IQVIA during the 1st quarter worth approximately $76,328,000. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

IQV stock opened at $216.43 on Monday. The firm has a market cap of $36.86 billion, a PE ratio of 29.69, a P/E/G ratio of 2.42 and a beta of 1.34. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03. The business has a 50 day moving average of $197.12 and a 200-day moving average of $174.12. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $225.91.

IQVIA (NYSE:IQV) last posted its quarterly earnings data on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, beating the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter in the prior year, the business earned $2.84 earnings per share. IQVIA’s revenue for the quarter was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.60% of the stock is owned by insiders.

Analyst Ratings Changes

IQV has been the topic of a number of research reports. Barclays upped their price target on IQVIA from $185.00 to $200.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 2nd. Robert W. Baird set a $258.00 price target on IQVIA and gave the stock an “outperform” rating in a research note on Wednesday. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday. Hsbc Global Res raised IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Thursday, October 9th. Finally, Baird R W raised IQVIA from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 29th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $241.41.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.